Search Published Scientific Projects Competitive Products and Technology Patents
Login
Vector NTI® software is a completely integrated suite of sequence analysis and design tools that help you manage, view, analyze, transform, share, and publicize diverse types of molecular biology data, all within one graphically rich analysis environment.
Industry:
Life Sciences
Owner:
Life Technologies Corporation (Invitrogen, Geneart, Aplied Biosistems)
Combining the convenience of the Invitrogen™ online ordering system, with cutting-edge GeneArt® service offerings.
Industry:
Life Sciences
Owner:
Life Technologies Corporation (Invitrogen, Geneart, Aplied Biosistems)
Their technology platform is based on manipulation of the genetic instructions of microbes for making natural product polyketides. Rearranging the modular units in natural polyketide synthases, combining modules from different enzymes, and incorporating n
Industry:
Pharma
Owner:
Bristol Myers
Genomic research has always relied on substantial computing infrastructure, and that need has only increased with the vast amounts of data that our teams have generated. Since our inception we have been pioneers in developing the most unique and efficient
Industry:
Life Sciences
Owner:
J Craig Venter Institute
Synthetic genomics combines methods for the chemical synthesis of DNA with computational techniques to design it. These methods allow scientists and engineers to construct genetic material that would be impossible or impractical to produce using more conv
Industry:
Life Sciences
Owner:
J Craig Venter Institute
The ability to routinely write the software of life will usher in a new era in science, and with it, new products and applications such as advanced biofuels, clean water technology, and new vaccines and medicines. The field is already having an impact in
Industry:
Life Sciences
Owner:
J Craig Venter Institute
Cell systems informatics permits faster design as well as efficient testing and learning about new gene targets or product pathways. This technology applies our proprietary bioinformatics software and database systems with our comprehensive knowledge of g
Industry:
Life Sciences
Owner:
Intrexon Corporation
Cell Identification and Purification: Specifically targeting and isolating cells of interest Our LEAP™ (Laser Enabled Analysis and Processing) cell processing instrumentation has set new standards for advancing the fields of cell analysis, purificatio
Industry:
Life Sciences
Owner:
Intrexon Corporation
Our Better DNA® approach seeks to facilitate the development of bio-based technologies to monitor, remediate and protect our environment with an appropriate balance of efficacy, sustainability and economic viability. As a result of industrialization and t
Industry:
Life Sciences
Owner:
Intrexon Corporation
The Neurospora platform is an extremely fast and cost-effective production platform for generating protein biologics. The platform utilizes the filamentous fungus Neurospora crassa (red bread-mold), which has a well-annotated haploid genome allowing for s
Industry:
Life Sciences
Owner:
Intrexon Corporation
The Agaricus platform is a proprietary mushroom-based transformation technology, which enables improvements in button mushroom crop trait development, including yield, disease, and quality traits. Each year the United States produces approximately 700 mil
Industry:
Agro
Owner:
Intrexon Corporation
The UltraVector® platform is an operating system comprising advanced DNA construction technologies, cellular and protein engineering, computational models and statistical methods which facilitate the rapid design, testing and production of complex biologi
Industry:
Chemical
Owner:
Intrexon Corporation
mAbLogix™ platform enables production of human B-cell libraries for isolation of fully human monoclonal and polyclonal antibodies. Our laser-enabled analysis and processing (LEAP™) instrument can identify and purify high antibody-expressing cells of inte
Industry:
Pharma
Owner:
Intrexon Corporation
Intrexon’s UltraCART Initiative integrates a number of proprietary synthetic biology technologies including RheoSwitch®, UltraVector®, AttSite®, mAbLogix™, Protein Engineering, and Laser-Enabled Analysis and Processing (LEAP™) platforms to overcome these
Industry:
Pharma
Owner:
Intrexon Corpororation
RTS® Controlled MicroRNA (miRNA) represents a class of bioactive RNA that can affect gene transcription and translation. Various studies have shown that miRNA expression levels can differ between healthy and diseased tissues. Rescuing natural miRNA expr
Industry:
Pharma
Owner:
Intrexon Corpororation
Intrexon's RheoSwitch Therapeutic System® (RTS®) platform can be applied to create high value therapeutics through controlled cellular expression of therapeutic proteins of interest. To enable inducible control over cellular function and optimized biolo
Industry:
Pharma
Owner:
Intrexon Corporation
The Gen9 BioFab® platform was conceived, designed and implemented to fill the gene synthesis void. As researchers’ understanding of gene sequence data increases, their ability to design and improve genes, pathways and organisms using synthetic biology tec
Industry:
Life Sciences
Owner:
Gen9, Inc.
Fabrus leverages its engineering expertise and flexible library technology to quickly optimize antibody leads. Multiple optimization criteria facilitate rational development of leads, including: affinity maturation, functional maturation, and robust expre
Industry:
Pharma
Owner:
Fabrus, LLC
Fabrus, Inc. combines advances in genomics, gene synthesis, high throughput protein production, and high throughput screening to generate a fully human germline IgG library secreted from mammalian cells. Fabrus libraries are rationally designed for struc
Industry:
Pharma
Owner:
Fabrus, LLC
Fabrus arrayed antibody libraries comprise fully human germline IgGs. Built from the human genome sequences encoding naturally-produced antibodies, we make each antibody in a single well. Our human library eliminates the need for humanization of early lea
Industry:
Pharma
Owner:
Fabrus, LLC